Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret by McBrayer, Alexis et al.
McBrayer et al. Virology Journal 2010, 7:149
http://www.virologyj.com/content/7/1/149
Open Access SHORT REPORT
© 2010 McBrayer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Short report Course of seasonal influenza A/Brisbane/59/07 
H1N1 infection in the ferret
Alexis McBrayer1, Jeremy V Camp1, Ron Tapp1, Vladimir Yamshchikov1, Sheila Grimes1, Diana L Noah1, 
Colleen B Jonsson1,2 and Carl E Bruder*1,3
Abstract
Every year, influenza viruses infect approximately 5-20% of the population in the United States leading to over 200,000 
hospitalizations and 36,000 deaths from flu-related complications. In this study, we characterized the immune and 
pathological progression of a seasonal strain of H1N1 influenza virus, A/Brisbane/59/2007 in a ferret model. The 
immune response of the animals showed a dose-dependent increase with increased virus challenge, as indicated by 
the presence of virus specific IgG, IgM, and neutralizing antibodies. Animals infected with higher doses of virus also 
experienced increasing severity of clinical symptoms and fever at 2 days post-infection (DPI). Interestingly, weight loss 
was more pronounced in animals infected with lower doses of virus compared to those infected with a higher dose; 
these results were consistent with viral titers of swabs collected from the nares, but not the throat. Analyzed specimens 
included nasal and throat swabs from 1, 3, 5, and 7 DPI as well as tissue samples from caudal lung and nasal turbinates. 
Viral titers of the swab samples in all groups were higher on 1 and 3 DPI and returned to baseline levels by 7 DPI. 
Analysis of nasal turbinates indicated presence of virus at 3 DPI in all infected groups, whereas virus was only detected 
in the lungs of animals in the two highest dose groups. Histological analysis of the lungs showed a range of pathology, 
such as chronic inflammation and bronchial epithelial hypertrophy. The results provided here offer important 
endpoints for preclinical testing of the efficacy of new antiviral compounds and experimental vaccines.
Findings
Every year, influenza virus infects 5-20% of the US popu-
lation with numerous deaths attributed to primary influ-
enza infection or secondary bacterial pneumonia [1]. The
rapid evolution of new influenza virus strains and drug
resistant variants demands constant development of
treatments as well as reliable animal models allowing for
testing of these remedies [2,3]. Although a number of ani-
mal models are used for influenza research, ferrets are
ideal because they can be readily infected with human
isolates of influenza virus (in contrast to mice) and
exhibit symptoms similar to humans, such as fever,
coughing, sneezing, runny nose, lethargy [4-10], and
make a full recovery in 7-10 days [11,12]. Humans and
ferrets also share a similar distribution of α-2,6 and α-2,3
linked sialic acid residues, which serve as the receptor for
influenza attachment to airway epithelial cells, enabling
influenza to use the same cell entry mechanism [5,13,14].
Furthermore, ferrets are large enough to easily monitor
aspects of disease progression and yield enough materials
for immunological and virological analysis, [6,15-17].
Prior to clinical trials, safety and efficacy need to be dem-
onstrated in two animal models, one non-rodent, making
the ferret ideal.
We examined progression of A/Brisbane/59/2007 in
ferrets using a full series of endpoints; clinical symptoms,
gross and microscopic pathology, virology, and immunol-
ogy. A/Brisbane/59/07 was obtained from the Centers for
Disease Control and Prevention and propagated for 2
days at 34°C in 10-day embryonated hen's eggs [18]. Cas-
trated and de-scented Fitch ferrets (6-8 months of age,
800-1800 grams; Triple F Farms, Sayre, PA) were assigned
to one of 6 treatment groups (Table 1) by a weight-
matched computer-generated randomization procedure.
Five groups were challenged intranasally with increasing
doses of A/Brisbane/59/2007, and controls received PBS.
Changes in body temperature, body weight, and onset of
clinical symptoms were monitored for 7 days after chal-
lenge to measure disease progression and severity. Ana-
* Correspondence: carl.bruder@gmail.com
1 Southern Research Institute, 2000 9th Ave South, Birmingham, AL 35205, USA
Full list of author information is available at the end of the articleMcBrayer et al. Virology Journal 2010, 7:149
http://www.virologyj.com/content/7/1/149
Page 2 of 5
lyzed specimens included blood sera, and excreta
samples from nasal and throat swabs from 1, 3, 5, and 7
DPI and tissues from 3 and 7 DPI. Animal studies were
approved by Southern Research Institutional Animal
Care and Use Committee and met the recommended ani-
mal care guidelines.
Animals in groups infected with higher doses of influ-
enza experienced greater severity in clinical symptoms
compared to those in lower dose groups or control ani-
mals (Table 1). Groups infected with influenza demon-
strated significant weight loss at 2 through 7 DPI
compared to the control group. Animals also exhibited
elevated body temperature on 2 DPI. Flu-like symptoms,
such as sneezing, and nasal and ocular discharge were
seen. Most animals fully recovered by 7 DPI; however,
some animals relapsed with a recurrence of clear or
serous nasal discharge. Histological analysis of lungs
showed a range of pathology, such as bronchiolar epithe-
lial hypertrophy and inflammation. Macroscopic lung
lesions consisted of dark/mottled discoloration observed
in animals in all dose groups on 3 and 7 DPI. In animals
euthanized on 3 and 7 DPI, microscopic lesions consis-
tent with influenza infection were observed in all chal-
lenge groups, but not controls. Microscopic lesions in
lungs of influenza challenge dose groups consisted of
acute inflammation of the alveolus, bronchiole, and bron-
chiole lumen; chronic inflammation of the alveolus, bron-
chus, peribronchiolar interstitium and perivascular
interstitium; chronic-active inflammation of the alveolus;
hemosiderin pigmentation of the perivascular intersti-
tium; type II pneumocyte hyperplasia; bronchiolar hyper-
trophy; syncytia of the alveolus and bronchiole; and
regeneration of the bronchiole. Although the incidence
and severity of lesions was variable among dose groups,
these parameters tended to be the greatest in animals
infected with higher doses of virus. Excluding chronic
inflammation of the perivascular interstitium and bron-
chiolar hypertrophy, which ranged from minimal to mild
in severity, lesions noted were minimal in severity (Figure
1).
Viral load in swabs and tissues was analyzed by titration
to determine the TCID50. Briefly, MDCK cells (ATCC,
clone CCl-34) were grown in DMEM (4.5 g/L glucose,
10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine,
0.25 M HEPES (all from Gibco)) and seeded at a density
of 30,000 cells per well in 96-well plates then incubated at
37°C overnight. For infection, UltraMDCK media
(Lonza) (2 μg/mL Trypsin, 1% penicillin/streptomycin,
1% L-glutamine, and 2.5% HEPES) was used. Cells were
inoculated with 10-fold serially diluted samples from
swabs or tissue homogenates in quadruplicate format.
Plates were incubated 3 days at 37°C, 5% CO2 and satu-
rated humidity, after which cytopathic effect (CPE) was
observed microscopically. The viability was determined
using a cell viability assay for the nasal and throat swabs
as well as for the nasal turbinates (Cell Titer Aqueous
One Reagent, Promega). The lungs were analyzed using A
cell based ELISA, since this method proved to be less sen-
Table 1: Study design and outline of clinical symptoms
Dose Group Challenge Material Infectious dose* Symptoms
1P B S - -N o n e
2 A/Brisbane/59/2007 103.8 Discharge, Nose, Serous
Discharge, Nose Purulent
Discharge, Eye, Clear
3 A/Brisbane/59/2007 104.8 Discharge, Nose, Serous
4 A/Brisbane/59/2007 105.8 Discharge, Nose, Clear
Discharge, Eye, Clear
5 A/Brisbane/59/2007 106.8 Discharge, Nose, Serous
Discharge, Eye, Clear
Sneezing
6 A/Brisbane/59/2007 107.8 Discharge, Nose, Clear
Discharge, Nose, Serous
Discharge, Eye, Clear
Sneezing
* Infectious dose is measured as 50% egg infectious dose per mL (EID50/mL)McBrayer et al. Virology Journal 2010, 7:149
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sitive to cell toxicity. Briefly, cell plates washed twice with
PBS (300 uL/well) and fixed (80% v/v Acetone, 50 μL/
well). After three repeats of PBS rinses followed by 10
min RT incubations, mouse-anti-nucleoprotein and
mouse anti-matrix protein antibodies (200 ng/mL, 50 μL/
well, ATCC) were added. The plates were then incubated
for 1 h at RT and washed three times with 300 μL/well of
PBS + 0.05% Tween-20 (PBST), after which 200 ng/mL of
HRP-conjugated horse anti-mouse IgG (H + L chains)
was added to (50 uL per well) and incubated for 1 h at RT.
Finally, the plates were developed using TMB 2-compo-
nent microwell peroxidase substrate kit (KPL). The reac-
tion was stopped using 1 M H3PO4, and plates were
measured at an absorbance of 450 nm. Analysis of nasal
turbinates collected on 3 DPI showed similar titers
regardless of viral dose administered at challenge. T wo
animals from group 6 and one animal from group 5
showed presence of virus in the lungs (Figure 2A). Results
showed dose-dependent infection in throat swabs for 1
and 3 DPI. Dose dependence is also seen for the nasal
swabs on 1 DPI (Spearman-Rho non-parametric testing,
rs > 0.85, Figure 2B and 2C). By 7 DPI, all groups returned
to baseline levels, indicating that the animals cleared the
infection (Figure 2B and 2C).
Immunological parameters were evaluated using virus
specific ferret IgG and IgM ELISA on sera collected on 3
and 7 DPI. Briefly, plates were coated with 1:200 dilution
of stock virus in PBS overnight at 4°C, blocked with 2%
donor goat serum (Sigma Aldrich) in PBS/0.05% v/v
Tween-20 for one hour. Ferret serum was then added and
2-fold serially diluted and incubated at 4°C overnight.
Anti-ferret IgG or IgM-HRP (1:10,000) (Rockland Immu-
nochemicals) was then added and after a one hour incu-
bation at 37°C, TMB substrate was added, the reaction
was stopped using 1 M H3PO4, and read at absorbance of
450 nm. At 7 DPI, influenza-specific IgM and IgG anti-
bodies increased relative to viral dose administered at
challenge (Spearman-Rho non-parametric testing, rs  >
0.94, Figure 3A and 3B). No change between pre-immune
and post-immune sera collected at 3 DPI was detected.
Neutralization titer analysis was performed to detect
influenza-specific neutralizing antibodies in serum. Only
sera collected on 7 DPI was evaluated as ELISA results
suggested that no neutralizing antibodies were present on
3 DPI. As expected, no neutralizing antibodies were
detected in sera from control animals. Only 2 of 4 ani-
mals from group 2 and 1 of 4 animals from group 3 had
detectable neutralizing antibodies; however neutralizing
antibodies were seen in all animals in groups 4, 5 and 6
which were challenged with higher doses of virus (Figure
3C). Hematological analyses were also performed on
blood samples collected immediately prior to euthanasia.
Results showed an increase in the number of lympho-
cytes, neutrophils, and the total number of white blood
cells in infected groups compared to control (Figure
3D,E,F). There was only a slight increase in the number of
basophils and eosinophils in groups 4 and 5 compared to
controls.
To conclude, ferrets infected with A/Brisbane/59/2007
H1N1 displayed mild clinical symptoms, with weight loss,
Figure 2 TCID50 Virus Titration Analysis. Blue dots indicate the titer 
of individual animals, the red line indicates the average for the animals 
tested in each group and day. For the caudal lung and nasal turbinates 
(A), four animals per group were analyzed at 3 DPI. In (B), analysis of 
throat and nasal swabs isolated at 1, 3, 5, and 7 DPI is shown. Eight sam-
ples per group were analyzed on 1 and 3 DPI, and four samples per 
group were analyzed on days 5 and 7 due to the euthanasia of 50% of 
the animals on 3 DPI.
Figure 1 Clinical Pathology of A/Brisbane/59/2007 infected fer-
rets. (A) Control lung tissue; (B) Lung from ferret challenged with 103.8 
EID50/ml with chronic inflammation in the bronchial glands; (C). Lung 
from ferret challenged with 104.8 EID50/ml with bronchiolar epithelial 
hypertrophy (white arrow) and, neutrophils and macrophages within 
alveoli and airways (black arrow); (D). Lung of ferret challenged with 
106.8 EID50/ml with a syncytium within an alveolus (see blue arrow). Im-
ages were taken at 400x magnification
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sneezing, nasal and ocular discharge as well as histo-
pathological lesions consistent with influenza infection.
Histopathology of the lungs indicated a localized immune
response. Virus titers exhibit dose dependence, with
higher titers early in the course of infection for the higher
doses. Lower doses suggest a delay of virus replication in
the samples tested. Homogenized nasal turbinates
showed a relatively even distribution over time points. In
contrast to a recently published study investigating the
pathological effects of a single dose of A/Brisbane/59/
2007 [19], we detected replicating virus in the lungs,
which indicates that this influenza strain is capable of
inducing infection in tissues of the lower respiratory
tract. High correlation is seen between viral dose at chal-
lenge and the immune response detected by virus specific
IgG and IgM ELISA, the neutralization index, and to the
viral titers of the throat swabs. To conclude, we describe
development of a ferret model for analysis of a seasonal
influenza strain. The results provide key endpoints for
preclinical testing of the efficacy of new antiviral com-
pounds and experiential vaccines.
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Figure 3 Humoral and Cellular Immunity. (A and B) ELISA data show 
an increase in influenza specific IgM and IgG at 7 DPI compared to 
mock-infected control animals. These data show that there is a dose-
dependent increase in antibody response. Bars indicate the average 
difference per group between log2-transformed end-point dilutions 
from pre-infection serum and post-infection serum. (C) Neutralization 
titer analysis was performed in order to detect the presence of influen-
za-specific neutralizing antibodies in the serum. The presence of neu-
tralizing antibodies was measured only on 7 DPI. No neutralizing 
antibodies were detected in the sera from control animals. Only 2 out 
of 4 animals from group 2 and 1 out of 4 animals from group 3 had de-
tectable neutralizing antibodies, while all animals in groups 4, 5, and 6 
had detectable neutralizing antibodies. (D, E, and F) The number of 
neutrophils and lymphocytes, as well as the total number of white 
blood cells, increased in animals infected with A/Brisbane/59/07 com-
pared to mock infected control animals. Y axis indicates number of 
cells as 103 cells per mm3.
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